Sana Biotechnology, Inc. (SANA)
NASDAQ (NGS) NASDAQ (NGS) Primary 
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
NEW YORK, NY / ACCESSWIRE / December 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
NEW YORK, NY / ACCESSWIRE / December 15, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus
Sana Biotechnology results from the phase 1 study using SC291 for the treatment of patients with SLE are expected in 2025. The FDA's Fast Track Designation for SC291 could expedite its review, addressing unmet medical needs in autoimmune disorders. Sana is also developing SC262 for relapsed/refractory B-cell malignancies, with data expected by the end of 2024 or in 2025.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
NEW YORK CITY, NY / ACCESSWIRE / November 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
NEW YORK CITY, NY / ACCESSWIRE / November 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
NEW YORK, NY / ACCESSWIRE / November 22, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
ATTENTION SANA SHAREHOLDERS: Investors who lost money on Sana Biotechnology, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
NEW YORK, NY / ACCESSWIRE / November 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. ("Sana Biotechnology, Inc.") (NASDAQ:SANA) concerning possible violations of federal securities laws. Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs".
